Last reviewed · How we verify

NCT03840460: PaC-MAn

A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Status unknown Last updated 20 February 2020
What this trial tests

trial in Pancreatic Adenocarcinoma in 200 participants. Status unknown.

Timeline
10 January 2019
Primary endpoint
10 January 2023
10 January 2023

Quick facts

Lead sponsorRoyal Marsden NHS Foundation Trust
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date10 January 2019
Primary completion10 January 2023
Estimated completion10 January 2023
Sites1 location across United Kingdom

Conditions studied

Sponsor

Royal Marsden NHS Foundation Trust

Who can join

18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are several types of early pre-cancerous lesions found in the pancreas which have the potential to develop into pancreatic cancer. Although different patients' pancreatic cancers or pre-cancerous pancreatic lesions have many similarities we believe that subtle differences can affect how they behave and therefore influence individual patient outcomes. Many factors may account for the differences seen in pancreatic lesion behaviour, for example molecular and genetic differences (the DNA and RNA present which control how a cell grows and divides), differences in how the immune system responds to the lesion, differences in the environment immediately around the lesion in the pancreas, known as the tumour microenvironment and differences in the micro-organisms which colonize a particular patient, known as their microbiota . This project studies the molecular makeup of pancreatic lesions and their microenvironment at various stages (from pre-cancerous lesions all the way through to more advanced disease) to see if we can use this information to divide patients into different groups whose lesions may behave in similar ways. We will be trying to find out if there are molecular reasons why some patients respond to particular treatments when others do not, why some patients experience more toxicity with particular treatments and why some patients' disease behaves particularly aggressively when other patients' disease does not. We will also be investigating the particular micro-organisms colonizing individual patients to see if these impact a patient's outcome. Understanding what makes one person's pancreatic lesion behave differently to another's could lead to better treatment, where a personalized therapeutic strategy could be applied for every single patient.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. microRNA-based diagnostic and therapeutic applications in cancer medicine.
    Sempere LF, Azmi AS, Moore A. · · 2021 · cited 97× · PMID 33998154 · DOI 10.1002/wrna.1662
  2. The role of microbiome in pancreatic cancer.
    Li JJ, Zhu M, Kashyap PC, Chia N, et al · · 2021 · cited 39× · PMID 34455517 · DOI 10.1007/s10555-021-09982-2
  3. Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.
    Seyhan AA. · · 2023 · cited 36× · PMID 37686149 · DOI 10.3390/ijms241713340
  4. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.
    Bocchini M, Nicolini F, Severi S, Bongiovanni A, et al · · 2020 · cited 36× · PMID 32537434 · DOI 10.3389/fonc.2020.00831
  5. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer.
    Abdul Rahman R, Lamarca A, Hubner RA, Valle JW, et al · · 2021 · cited 24× · PMID 34359684 · DOI 10.3390/cancers13153779
  6. The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance.
    Martinez-Useros J, Martin-Galan M, Garcia-Foncillas J. · · 2021 · cited 22× · PMID 33477288 · DOI 10.3390/cancers13020322
  7. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma.
    Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, et al · · 2020 · cited 22× · PMID 33287196 · DOI 10.3390/biomedicines8120565
  8. Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut.
    Yu Q, Jobin C, Thomas RM. · · 2021 · cited 21× · PMID 33418277 · DOI 10.1016/j.neo.2020.12.008

Verify or expand the search:

Other recruiting trials for Pancreatic Adenocarcinoma

Currently open trials in the same condition.

Other Royal Marsden NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03840460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing